← 10x Genomics, Inc.
| Annual Trend | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|---|---|---|
| Cash and cash equivalents | $65.1m | $424.2m | $663.6m | $587.4m | $219.7m | $359.3m | $344.1m | $474.0m | |
| Accounts receivable, net | $28.1m | $33.4m | $51.2m | $85.3m | $104.2m | $114.8m | $87.9m | $47.0m | |
| Inventory | $8.6m | $15.3m | $30.0m | $60.0m | $81.6m | $73.7m | $83.1m | $56.3m | |
| Other receivables | — | — | — | — | — | — | $606k | $35.5m | |
| Prepaid expenses and other current assets | $4.5m | $8.0m | $13.0m | $13.9m | $16.6m | $18.8m | $20.0m | $22.2m | |
| Total current assets | $106.2m | $480.8m | $774.4m | $747.6m | $635.0m | $596.0m | $584.4m | $684.5m | |
| Property and equipment, net | $11.1m | $48.8m | $72.8m | $169.5m | $289.3m | $279.6m | $252.6m | $226.7m | |
| Goodwill | — | — | $0 | $4.5m | $4.5m | $4.5m | $4.5m | $4.5m | |
| Intangible assets, net | — | — | $22.4m | $25.4m | $22.9m | $16.6m | $15.7m | $62.3m | |
| Operating lease right-of-use assets | — | — | $47.0m | $60.9m | $69.9m | $65.4m | $57.3m | $60.5m | |
| Other noncurrent assets | $1.9m | $23.9m | $26.7m | $3.3m | $2.4m | $3.1m | $4.1m | $2.9m | |
| Marketable securities | — | — | — | $0 | $210.2m | $29.4m | $49.3m | $49.4m | |
| Accrued expenses and other current liabilities | $9.9m | $24.4m | $43.5m | $50.9m | $59.8m | $56.6m | $41.2m | $40.0m | |
| Deferred revenue | $2.4m | $3.3m | $4.5m | $5.3m | $7.9m | $13.2m | $20.7m | $23.9m | |
| Operating lease liabilities | — | — | $5.9m | $5.1m | $9.0m | $11.5m | $9.3m | $11.0m | |
| Contingent consideration, current | — | $0 | $44.2m | $0 | — | — | $0 | $23.4m | |
| Contingent consideration, noncurrent | — | — | — | — | — | — | $0 | $1.2m | |
| Operating lease liabilities, noncurrent | — | — | $57.0m | $76.8m | $86.1m | $83.8m | $73.3m | $73.4m | |
| Total stockholders’ equity | ($220.0m) | $420.1m | $739.1m | $817.6m | $805.7m | $741.0m | $710.1m | $796.3m | |
| Total assets | $124.3m | $605.9m | $929.3m | $1.0b | $1.0b | $965.1m | $918.6m | $1.0b | |
| Total liabilities and stockholders’ equity | $124.3m | $605.9m | $929.3m | $1.0b | $1.0b | $965.1m | $918.6m | $1.0b | |
| Accounts payable | $8.8m | $13.0m | $4.7m | $17.4m | $21.6m | $15.7m | $12.9m | $12.7m | |
| Accrued compensation and related benefits | $7.0m | $12.4m | $15.4m | $31.6m | $32.7m | $30.1m | $33.6m | $42.5m | |
| Deferred revenue, noncurrent | $1.1m | $834k | — | — | $3.2m | $8.8m | $12.5m | $10.5m | |
| Total current liabilities | $32.4m | $63.0m | $118.1m | $110.4m | $131.0m | $127.2m | $117.6m | $153.5m | |
| Other noncurrent liabilities | $771k | $1.1m | $3.9m | $8.2m | $6.1m | $4.3m | $5.0m | $6.5m | |
| Total liabilities | $101.1m | $185.8m | $190.3m | $201.3m | $223.2m | $224.1m | $208.5m | $245.0m | |
| Preferred stock, $0.00001 par value; 100,000,000 shares authorized, no shares issued or outstanding as of December 31, 2025 and 2024 | — | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Common stock, $0.00001 par value; 1,100,000,000 shares authorized (Class A 1,000,000,000, Class B 100,000,000); 127,691,329 (Class A 117,612,457, Class B 10,078,872) and 122,291,837 (Class A 108,235,004, Class B 14,056,833) shares issued and outstanding as of December 31, 2025 and 2024, respectively | 1k | 2k | 2k | 2k | 2k | 2k | 2k | 2k | |
| Additional paid-in capital | $11.2m | $682.5m | $1.5b | $1.7b | $1.8b | $2.0b | $2.2b | $2.3b | |
| Accumulated deficit | ($231.1m) | ($262.4m) | ($805.1m) | ($863.3m) | ($1.0b) | ($1.3b) | ($1.5b) | ($1.5b) | |
| Accumulated other comprehensive income (loss) | ($37k) | ($46k) | ($50k) | $22k | ($4.3m) | ($429k) | ($493k) | $225k |
Values abbreviated: b = billions, m = millions, k = thousands. Per share data in USD.